Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
6. Combining Targeted Drugs Is Worse in Colorectal Cancer 3
(Posted: 02/24/2009) - A clinical trial testing chemotherapy combined with bevacizumab (Avastin) and cetuximab (Erbitux), and comparing this with chemotherapy and bevacizumab alone, found that the addition of cetuximab was actually worse for patients, according to the Feb. 5, 2009, New England Journal of Medicine.
7. Removal of Ovaries and Fallopian Tubes Cuts Cancer Risk for BRCA1/2 Carriers 4
(Posted: 02/24/2009) - Surgery that removes the ovaries and fallopian tubes is one of the most effective ways to decrease a woman's risk of breast and gynecologic cancer if she carries a BRCA1 or BRCA2 gene mutation, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
8. Radiation Plus Hormone Therapy for Locally Advanced Prostate Cancer Improves Survival 5
(Posted: 02/03/2009) - Clinical trial results published online December 15, 2009, in The Lancet, affirms earlier studies showing that adding radiation therapy to hormone therapy (HT) is more effective than HT alone for locally advanced prostate cancer.
9. 5-FU-Based Chemotherapy Cures Some Patients with Colon Cancer 6
(Posted: 02/03/2009) - Researchers from the Adjuvant Colon Cancer Endpoints (ACCENT) Group used individual patient data from 18 phase III trials of adjuvant 5-FU-based chemotherapy for colon cancer to show that the regimens provide their survival benefit primarily by reducing the high risk of recurrence within the first two years after surgery, according to a study published online January 5, 2009, in the Journal of Clinical Oncology.
10. Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia 7
(Posted: 01/14/2009) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
< Previous 8 1 8 2 3 9 4 10 5 11 Next > 9
|
